• Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease

  NCT03283059

  Unknown statusInterventionalPhase 3Updated Oct 22, 2019
• Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

  NCT01282619

  Unknown statusInterventionalPhase 2Phase 3Updated Jan 25, 2011
• Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

  NCT07066826

  RecruitingInterventionalPhase 2Phase 3Updated Aug 17, 2026
• Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease

  NCT05811442

  CompletedInterventionalPhase 2Updated Sep 18, 2025
• Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease

  NCT00359944

  CompletedInterventionalPhase 2Updated Jul 2, 2013
• Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease

  NCT03790982

  Unknown statusInterventionalPhase 2Updated Jan 2, 2019

ClinicalTrials.gov ID

NCT01569516

Lead Sponsor

Changchun Huayang High-tech Co., LtdINDUSTRY

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 2

Enrollment

288Estimated

Last Update Posted

Apr 9, 2012Estimated

Start Date

Jun 2011

Primary Completion Date

Jul 2012Estimated

Completion Date

Oct 2012Estimated

Official Title

A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease

Brief Summary

The main purpose of this study is to evaluate the safety and efficacy of Octohydroaminoacridine Succinate tablets and find the optimal dose in patients with mild to moderate Alzheimer's Disease.

Detailed Description

The purpose of this study is a preliminary assessment of the Octohydroaminoacridine Succinate tablets in the treatment of mild to moderate Alzheimer's disease and explore the efficacy and safety of the best dose. The 288 patients were randomly assigned to four groups: high dose (4mg / time), moderate dose (2mg / time), low dose (1mg / time) and the placebo group, including four weeks of the trial screening period following 16 weeks double-blind treatment.

• Alzheimer's Disease

• Octohydroaminoacridine Succinate Tablets
• Octohydroaminoacridine succinate Tablets
• Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Clinical diagnosis of probable AD based on DSM-IV and the NINCDS-ADRDA criteria.
2. Male/female patient aged between 50 and 85.
3. mild to moderate probable AD ：Middle school or above: 11 ≤MMSE ≤ 25, elementary school: 8 ≤ MMSE ≤ 20, illiteracy: 5 ≤ MMSE ≤ 16.
4. CT or MRI scan excluding another structural brain disease in one year.
5. Neurologic examination no significant abnormalities.
6. Hachinski Ischemic Score < 4；Hamilton Depression Scale ≤10. Able to complete the test procedure, audio-visual and physical ability to act to complete the neuropsychological measure.
7. Stable chaperone, more than 2 hours a day together with the patient or accumulated fewer than 14 hours per week.
8. Informed consent of the patient (or legal representative) and of the caregiver agreeing to take part in the study.

Exclusion Criteria:

1. Proven or clinically suspected other type of dementia such as vascular dementia, Lewy body dementia, Parkinson's disease, frontotemporal dementia, g - Jakob disease (spastic pseudo-sclerosis), normal pressure hydrocephalus etc.
2. Sudden onset of early dementia or with gait disorders, seizures and behavioral changes.
3. Clinical manifestations of focal neurological signs (hemiparesis, sensory loss, visual field defect) or early extrapyramidal tract signs.
4. History of cerebrovascular disease and stroke.
5. Serious lack of folic acid and VitB12, syphilis antibody positive or thyroid dysfunction.
6. Mechanical intestinal obstruction patient ,Resting pulse less than 60,Severe liver or renal disease.
7. Patients with mechanical intestinal obstruction.
8. History of bone marrow transplantation.Mental illness, such as severe depression.
9. Cognitive damage caused by alcohol or drug abuse. Disable to correctly evaluate the cognitive function.
10. Critical condition, disable to make the exact evaluation of the efficacy and safety of new drug.
11. Use of any agent for the treatment of dementia within 4 weeks of randomization.
12. Be sensitive to ACHEI.
13. Be sensitive to two or more foods/drugs.
14. Use of another investigational agent within one months of screening.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

Changchun Huayang High-tech Co., LtdINDUSTRY

Collaborators

Beijing Bionovo Medicine Development Co., Ltd.OTHER

Lhly5@yahoo.com.cn86-21-64387250 ext. 3128